Clinical Trials Logo

Stimulant Use Disorder clinical trials

View clinical trials related to Stimulant Use Disorder.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05288751 Active, not recruiting - Opioid Use Disorder Clinical Trials

Contingency Management for Opioid and Stimulant Use Disorders in Primary Care

Start date: June 15, 2022
Phase: N/A
Study type: Interventional

Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting. When applied to the treatment of substance use disorders, it has demonstrated efficacy in reducing the number of urine toxicology screens positive for illicit substances and increased engagement in treatment programs. However, there is a need to translate CM treatment to primary care settings. This study will implement and assess a CM program for patients with opioid use disorder, with or without comorbid stimulant use disorder, initiating outpatient addiction medicine services at a family medicine residency clinic. Eligible patients will earn monetary incentives for attending addiction medicine appointments and abstaining from substances during outpatient treatment. Data gathered from this pilot program will be used to improve patient outcomes, treatment, and retention for persons receiving medications for opioid use disorder (MOUDs) in a primary care setting.

NCT ID: NCT04907357 Active, not recruiting - Cocaine Dependence Clinical Trials

rTMS for Stimulant Use Disorders

CTN-0108
Start date: February 4, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to determine feasibility of repetitive transcranial magnetic stimulation (rTMS) for individuals with moderate to severe cocaine or methamphetamine use disorder (CUD/MUD). Potential participants will be age 18-65, and interested in cutting down or stopping use. Participants will be randomized to one of two groups; groups will receive rTMS or sham rTMS (placebo) over the course of an 8-week treatment period, and complete follow-up assessments at the end of treatment, 12, and 16 weeks post-randomization.